Drug General Information
Drug ID	D0I6KU
Former ID	DNC013722
Drug Name	5-(2-m-tolylethynyl)pyrimidine
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[529531]
Structure		Download 2D MOL 3D MOL
Formula	C13H10N2
Canonical SMILES	CC1=CC=CC(=C1)C#CC2=CN=CN=C2
InChI	1S/C13H10N2/c1-11-3-2-4-12(7-11)5-6-13-8-14-10-15-9-13/h2-4,7-10H,1H3
InChIKey	WDWDORGIXVCIQC-UHFFFAOYSA-N
PubChem Compound ID	24894087
Target and Pathway
Target(s)	Metabotropic glutamate receptor 5	Target Info	Inhibitor	[529531]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Long-term potentiation
	Retrograde endocannabinoid signaling
	Glutamatergic synapse
	Huntington's disease
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Metabotropic glutamate receptor group III pathway
	Metabotropic glutamate receptor group I pathway
	Endogenous cannabinoid signaling
Reactome	G alpha (q) signalling events
	Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways	Hypothetical Network for Drug Addiction
	GPCRs, Class C Metabotropic glutamate, pheromone
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 529531	Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. Epub 2008 May 29.Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold.
Ref 529531	Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. Epub 2008 May 29.Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.